




Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Transient optic neuritis and perineuritis associated with anti-MOG antibody after SARS-CoV-2 mRNA vaccination

Takaomi Singu^{a,*}, Makoto Nakajima^a, Akihiko Ueda^a, Keiichi Nakahara^a, Toshiya Nomura^a, Sachi Kojima^b, Toshihiro Inoue^b, Mitsuharu Ueda^a

^a Department of Neurology, Faculty of Life Sciences, Kumamoto University

^b Department of Ophthalmology, Faculty of Life Sciences, Kumamoto University

ARTICLE INFO

Keywords:

Optic neuritis

Sars-cov-2 vaccination

Transient visual field abnormality

ABSTRACT

Backgrounds: To report the first case of left optic neuritis and perineuritis associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 mRNA vaccination.

Case presentation: A 39-year-old woman was referred and admitted to our hospital due to transient left visual field abnormality with left ophthalmalgia and headache 12 days after the first vaccination dose of SARS-CoV-2 (BNT162b2). On admission (Day 2), she presented with left ophthalmalgia and headache without any other neurological deficits including the movement of eyeballs, visual field, visual acuity, or nystagmus. MRI on Day 2 suggested slight left optic neural swelling; Gadolinium-enhanced MRI on Day 4 revealed left optic perineuritis. Test for serum anti-aquaporin 4 antibody was negative, whereas anti-myelin oligodendrocyte glycoprotein (MOG) antibody was positive. She was diagnosed with left optic perineuritis after SARS-CoV-2 mRNA vaccination. Her visual disturbance never recurred and her ophthalmalgia and headache subsided only with anti-inflammatory agents.

Discussion: Many cases of optic neuritis associated with vaccinations have been reported except for SARS-CoV-2 BNT162b2 mRNA. To our knowledge, only one neuromyelitis optica case was associated with anti-MOG antibody. Therefore, we propose that SARS-CoV-2 mRNA vaccination may induce transient optic neuritis and perineuritis, associated with anti-MOG antibody in the present case.

Conclusion: This is the first case of left optic neuritis and perineuritis associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BNT162b2 mRNA vaccination.

A 39-year-old woman with a history of single caesarian resection got her first dose of severe acute respiratory syndrome coronavirus2 (SARS-CoV-2) BNT162b2 mRNA vaccine. Seven days after the vaccination, she experienced a sore throat, and bilateral parotid gland pain after further 10 days. These symptoms subsided within a few days of onset. Thirteen days after the vaccination (Day 0), she developed left ophthalmalgia and slight headache in the left side of the head. On Day 1, she developed visual disturbance; a star-like misty area emerged on her left visual field. This symptom lasted for only a few minutes. On Day 2, the same visual symptom recurred and subsided within a few minutes. She visited an ophthalmologist, but ophthalmologic examination revealed no specific findings. Nevertheless, she again developed visual disturbance like white-out on her left visual field. This symptom lasted 30 min and gradually subsided within 10 min. She visited a clinic and was referred to our hospital due to suspected amaurosis.

On admission, she presented with only left ophthalmalgia and headache without any other neurological deficits including the move-

ment of eyeballs, visual field, visual acuity, or nystagmus. The blood examination revealed no significant abnormality as follows: total protein, 7.3 g/dL; albumin, 4.3 g/mL; sodium/ potassium/ chloride, 139/ 4.0/ 106 mmol/L; blood urea nitrogen, 16.0 mg/dL; creatinine, 0.58 mg/dL; antinuclear antibody, 1:2.9; anti-double strand deoxyribonucleic acid, <1.2 IU/mL; anti SS-A antibody, <1.0 U/mL; anti SS-B antibody, <1.0 U/mL; myeloperoxidase antineutrophil cytoplasmic antibody, <0.5 IU/mL; cytoplasmic antineutrophil cytoplasmic antibody, <0.5 IU/mL; soluble interleukin 2 receptor, 235 U/mL; white blood cell count, $5.4 \times 10^3 /\mu\text{L}$; hemoglobin, 10.8 g/dL; hematocrit, 33.0%; platelet count, $221 \times 10^3 /\mu\text{L}$; PT-INR, 0.93; aPTT, 29.7 s.; and D-dimer level, <0.3 $\mu\text{g/mL}$. Cerebrospinal fluid (CSF) was waterly clear with normal opening pressure. On CSF analyses, total protein was 18.8 mg/dL and cell count was <1.0 $/\mu\text{L}$.

MRI on admission (Day 2) suggested slight left optic neural swelling; Gadolinium-enhanced MRI on Day 4 revealed left optic neuritis and perineuritis (Fig. A, C). Serum anti-aquaporin 4 antibody was negative,

* Corresponding author at: Honjo 1-1-1, Chuo-Ku, Kumamoto-City, Kumamoto 860-8556, Japan.

E-mail address: takaomi.sing@gmail.com (T. Singu).




Fig. 1. Gadolinium-enhanced T1 fat-suppressed (FS) three-dimensional turbo spin-echo (3D-TSE) images A, C: Axial (A) and coronal (C) images at admission demonstrated significant enhancement of left anterior optic nerve and perineural sheath (arrowhead). B, D: Axial (B) and coronal (D) images on Day 58 revealed significant resolution of enhancement (arrowhead).

whereas anti-myelin oligodendrocyte glycoprotein (MOG) antibody was positive. She was diagnosed with left optic neuritis and perineuritis associated with SARS-CoV-2 mRNA vaccination. Her visual disturbance never recurred and her ophthalmalgia and headache subsided only with anti-inflammatory agents. She was discharged on Day16 and was followed up at outpatient of our hospital. Gadolinium-enhanced MRI on Day 58 demonstrated significant effacement of the enhancement in the optic nerve and perineural sheath (Fig. 1B, D).

In general, vaccinations are associated with central nervous demyelinating diseases including optic neuritis, acute disseminated encephalomyelopathy, myelitis, and encephalopathy (Dimitrios et al., 2014; Kumar et al., 2020), which are overlapped each other (Kumar et al., 2020). One of the most frequent demyelinating diseases associated with vaccinations is optic neuritis (Kumar et al., 2020). Furthermore, among post-vaccination central nerve demyelinating diseases, optic neuritis alone without overlapping with others was relatively common compared to other syndromes (Dimitrios et al., 2014). Patients with demyelinating disease in the central nervous system associated with vaccination are treated with mainly steroids (Dimitrios et al., 2014; Kumar et al., 2020). Other options are plasmapheresis, intravenous immunoglobulin, and other immunosuppressants such as rituximab (Dimitrios et al., 2014; Kumar et al., 2020). Most patients with central demyelinating diseases associated with vaccination achieve almost complete recovery or remission (Dimitrios et al., 2014; Kumar et al., 2020), and the prognosis is generally good.

Focused on neuromyelitis optica spectrum disorder, and acute disseminated encephalomyelopathy, recent studies have revealed that the diseases are related to anti-MOG antibody. However, the relationship between vaccinations and anti-MOG antibody is rarely reported

(Kumar et al., 2020; Yaici et al., 2021; Azumagawa et al., 2016). To our knowledge, only three cases were reported with other non- SARS-CoV-2 vaccines. Among the three, only one patient who received Diphtheria, Tetanus, and Poliovirus vaccine developed bilateral optic neuritis associated with anti-MOG antibody (Yaici et al., 2021). Therefore, we speculate that SARS-CoV-2 mRNA vaccination may have induced transient optic perineuritis, associated with anti-MOG antibody in the present case.

Declarations of Competing Interest

None.

References

- Dimitrios, K., Panayioti, P., 2014. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. *Autoimmun Rev* 13 (3), 215–224. doi:10.1016/j.autrev.2013.10.003.
- Kumar, N., Graven, K., Joseph, N.I., et al., 2020. Case Report: postvaccination Anti-Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder: a Case Report and Literature Review of Postvaccination Demyelination. *Int J MS Care* 22 (2), 85–90. doi:10.7224/1537-2073.2018-104.
- Yaici, R., Carzoli, A., Bétis, F., Geerling, G., Guthoff, R., Guthoff, T., 2021. Atypische Neuritis nervi optici (NNO): bedeutung einer umfassenden Abklärung [Atypical optic neuritis: the importance of a comprehensive diagnostic work-up]. *Ophthalmologie* 118 (6), 593–596. doi:10.1007/s00347-020-01165-8, (German).
- Azumagawa, K., Nomura, S., Shigeri, Y., et al., 2016. Post-vaccination MDEM associated with MOG antibody in a subclinical Chlamydia infected boy. *Brain Dev* 38 (7), 690–693. doi:10.1016/j.braindev.2016.02.004.